HanAll Biopharma Turns to Profit with 1.1 Billion KRW Operating Income in Q2

Sales of 40.7 Billion KRW, Net Profit of 600 Million KRW

HanAll Biopharma announced on the 30th that, on a consolidated basis, its operating profit for the second quarter of this year reached 1.1 billion KRW, turning to a profit with an increase of 4.2 billion KRW compared to the same period last year, according to provisional figures.

HanAll Biopharma

Net profit also turned positive, reaching 600 million KRW. Revenue stood at 40.7 billion KRW, representing a 28.8% increase from the same period last year.

The company explained that steady growth in its key products, including 'Biotop', 'Eligard', and 'Normix', drove these results. In particular, the probiotic pharmaceutical 'Biotop' surpassed 10 billion KRW in sales in the first half alone, more than doubling compared to the same period last year.

In the research and development sector, the company reported that 'Batoclimab', a neonatal Fc receptor (FcRn) inhibitor therapy, showed excellent results in both autoantibody reduction rates and treatment response rates in phase 3 clinical trials for myasthenia gravis.

Jung Seungwon, CEO of HanAll Biopharma, stated, "Despite internal and external uncertainties, we achieved sales growth, and the development of our innovative pipeline that could change the paradigm of patient treatment is progressing smoothly." He added, "With phase 3 clinical trials for Batoclimab in thyroid eye disease planned for this year, and topline results for a dry eye treatment expected next year, a total of eight clinical results in autoimmune diseases are scheduled over the next three years. We will focus our capabilities on areas such as Parkinson's disease and anti-aging treatments, where there is an urgent need for new therapies."